FDA Appoints Dr. George Tidmarsh as New Head of the Center for Drug Evaluation and Research

On July 23, 2025, the U.S. Food and Drug Administration announced the appointment of Dr. George Francis Tidmarsh, M.D., Ph.D., as the new director of the Center for Drug Evaluation and Research (CDER). This pivotal role involves overseeing the safety, efficacy, and regulatory approval of a wide range of pharmaceuticals, including over-the-counter medications, prescription drugs, biologics, and generics, ensuring they meet stringent standards to protect public health.

Dr. Tidmarsh is a distinguished medical professional with a deep background in both clinical medicine and scientific research. He earned his Ph.D. in cancer biology from Stanford University, where he also completed residency training in pediatrics, along with subspecialty training in pediatric oncology and neonatology. With over 30 years of experience spanning biotechnology, medicine, and regulatory science, he is well-equipped to lead the agency's efforts in fostering pharmaceutical innovation and safety.

The FDA Commissioner, Marty Makary, M.D., M.P.H., praised Dr. Tidmarsh, highlighting his extensive experience as a physician-scientist and his comprehensive knowledge of the drug development process—from laboratory research to clinical application. His leadership is expected to enhance the FDA's drug review programs and promote initiatives that improve healthcare outcomes in the United States.

In addition to his regulatory role, Dr. Tidmarsh co-founded Stanford University's Master of Translational Research and Applied Medicine program, aimed at converting scientific discoveries into practical medical solutions. Throughout his career, he has contributed to the development of seven FDA-approved drugs and held leadership positions in various biopharmaceutical companies. His work focuses on advancing therapies for unmet medical needs while ensuring rigorous safety standards.

This appointment marks a significant milestone for the FDA, as it seeks to strengthen its role in ensuring safe drug access and fostering biomedical innovation.

For more information, visit FDA official announcement.